Stoke Therapeutics 3Q 2026: Revenue $11.3M, Net loss $73.6M, EPS $(1.08) — 10-Q Summary

What happened

Stoke Therapeutics reported third-quarter 2026 revenue of $11.3 million, up 5.9% from a year earlier, while its net loss widened to $73.6 million from $38.3 million. Diluted loss per share was $(1.08), compared with $(0.65) a year earlier.

Confirmed

Global impact / market context

Revenue growth was modest compared with the widening loss, indicating that current income did not offset the company’s reported costs. Continued losses can reduce cash available to fund research and preparations for a possible zorevunersen launch, making trial results and spending needs important to investors.

Analyst inference

The article describes a clinical-stage company whose business outlook depends on experimental treatments and future study results. The 201-patient EMPEROR trial is expected to report in the third quarter of 2027, while the planned U.S. filing is targeted for the second half of 2027.

Confirmed

What to watch

1. Watch for the EMPEROR Phase 3 results expected in the third quarter of 2027; the findings could shape the planned U.S. filing in the second half of 2027. Confirmed
2. Track whether quarterly revenue growth continues and whether losses widen, since the combination affects how much cash may remain for research and launch preparations. Analyst inference
3. Look for initial data from later OSPREY dose cohorts in the first half of 2027; the study is testing STK-002 for inherited optic nerve disease. Confirmed

Evidence

• Original source link unavailable